...
首页> 外文期刊>Mayo Clinic Proceedings >Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
【24h】

Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.

机译:B细胞慢性淋巴细胞性白血病/小淋巴细胞淋巴瘤中趋化因子受体CXCR4和CCR7的表达及疾病进展。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To assess the clinical relevance of chemokine receptor expression on the progression of B-cell chronic lymphocytic leukemia (B-CLL). PATIENTS AND METHODS: Peripheral blood mononuclear cells from 45 patients with B-CLL were purified and compared with lymph node samples collected from 17 of these patients. Also compared were B cells obtained from peripheral blood samples from 5 healthy controls and B cells from reactive lymph nodes from 3 otherwise healthy persons. The patients were treated at the Mayo Clinic in Rochester, Minn, between January 15,1991, and February 7, 2003. Mononuclear cells were stained by a 2-color (fluorescein isothiocyanate/phycoerythrin) flow cytometric assay using antibodies to the chemokine receptors (CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CCR2, CCR4, CCR5, CCR6, and CCR7) and also to CD19. RESULTS: Of the 45 patients in this study, 20 had Rai stage 0 disease, 12 had stage I disease, 3 had stage II disease, 2 had stage III disease, and 8 had stage IV disease. The mean fluorescent intensity (MFI) of the chemokine receptor expression on B-CLL cells was compared with normal controls and was not significantly different, except for an increase in the median expression of CXCR3 (P = .003) and CCR7 (P = .001) on B-CLL cells. We also found a significant increase in the expression of CXCR4 and CCR7 in B-CLL cells from patients with stage IV compared with stage 0 disease (P = .001 and P = .02, respectively). Furthermore, circulating B-CLL cells showed significantly higher expression of CXCR4 and CCR7 when compared with B lymphocytes in lymph nodes (P = .003 and P < .001, respectively). CONCLUSION: The expression of CXCR4 and CCR7 on B-CLL cells correlates with Rai stage. Also, these chemokine receptors may be down-regulated once malignant B cells enter the lymph nodes. To our knowledge, this is the first published report that shows the strong association of Rai stage with CXCR4 and CCR7 expression levels in B-CLL cells.
机译:目的:探讨趋化因子受体表达对B细胞慢性淋巴细胞白血病(B-CLL)进展的临床意义。患者与方法:纯化了45例B-CLL患者的外周血单个核细胞,并与其中17例患者的淋巴结样本进行了比较。还比较了从5个健康对照者的外周血样本中获得的B细胞和3个健康者的反应性淋巴结中获得的B细胞。在1991年1月15日至2003年2月7日之间,在明尼苏达州罗切斯特市的梅奥诊所对患者进行了治疗。单核细胞通过2种颜色(异硫氰酸荧光素/藻红蛋白)的流式细胞术使用趋化因子受体抗体进行染色( CXCR1,CXCR2,CXCR3,CXCR4,CXCR5,CCR2,CCR4,CCR5,CCR6和CCR7)以及CD19。结果:在该研究的45位患者中,有20位患有Rai 0期疾病,12位患有I期疾病,3位患有II期疾病,2位患有III期疾病,8位患有IV期疾病。将B-CLL细胞上趋化因子受体表达的平均荧光强度(MFI)与正常对照进行比较,除了CXCR3(P = .003)和CCR7(P =。 001)在B-CLL细胞上。我们还发现与0期疾病相比,IV期患者B-CLL细胞中CXCR4和CCR7的表达显着增加(分别为P = .001和P = .02)。此外,与淋巴结中的B淋巴细胞相比,循环中的B-CLL细胞显示出显着更高的CXCR4和CCR7表达(分别为P = .003和P <.001)。结论:BCLL细胞中CXCR4和CCR7的表达与Rai分期有关。而且,一旦恶性B细胞进入淋巴结,这些趋化因子受体可能会下调。据我们所知,这是第一个发表的报告,显示Rai期与B-CLL细胞中CXCR4和CCR7表达水平密切相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号